If you or your loved one used Dupixent and later received a diagnosis of cutaneous T-cell lymphoma (CTCL), you may be dealing with far more than medical uncertainty. You may be facing mounting bills, a frightening cancer diagnosis, questions about whether warning signs were missed, and a growing fear that your medication may have contributed to your CTCL diagnosis a worsening condition. These are serious concerns, and they deserve clear answers and careful legal attention.
At Spotlight Justice, we represent individuals and families pursuing dangerous drug and mass tort claims. We understand how overwhelming it can feel when faced with a cancer diagnosis. To help you make sense of what may come next, this article explains the concerns surrounding Dupixent and CTCL, the legal questions now emerging, and why it may be important to have your case reviewed promptly.
Cutaneous T-Cell Lymphoma Risk With Use of Dupixent
For many people, Dupixent offered hope after months or years of uncomfortable flare-ups, persistent itching, and frustration with treatments that no longer seemed to work. That is why growing concern about a possible connection between Dupixent and cutaneous T-cell lymphoma, or CTCL, has drawn such serious attention.
If you were prescribed this drug for eczema or another inflammatory condition and later received a lymphoma diagnosis, you may now be asking difficult questions about the cause of your diagnosis and whether legal action may be possible.
What Is Dupixent (Dupilumab)?
Dupixent, or dupilumab, is a prescription biologic medication used to treat several chronic inflammatory conditions, including eczema, also called atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. It has also been prescribed off-label in some situations beyond its FDA-approved uses, including reported use for conditions such as alopecia, chronic pruritus, lichen planus, and localized scleroderma.
For people living with atopic dermatitis, symptoms often cycle between periods of improvement and painful flare-ups that can interfere with sleep, comfort, and daily life. Dupixent is often prescribed for moderate to severe cases that are difficult to control with topical therapies alone. The medication targets specific immune pathways that drive inflammation in the body, which is one reason it has been viewed as an important treatment option for patients whose symptoms have been difficult to manage.
For patients who trusted this medication to help manage a serious and often debilitating skin condition, growing concern about a possible link between Dupixent and a rare form of lymphoma has raised deeply troubling questions.
What Is Cutaneous T-Cell Lymphoma (CTCL)?
Cutaneous T-cell lymphoma, or CTCL, is a rare group of non-Hodgkin lymphomas involving malignant T lymphocytes that often begin in the skin. In its earlier stages, CTCL may appear as patches, plaques, rashes, lesions, or tumors that can look similar to eczema or other chronic inflammatory skin disorders. That overlap is one reason this issue has become so concerning for patients who were prescribed Dupixent.
CTCL encompasses several distinct subtypes, including mycosis fungoides, Sézary syndrome, peripheral T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma, and extranodal natural killer/T-cell lymphoma. Mycosis fungoides is the most common form, while Sézary syndrome is a more aggressive variant in which malignant cells may also circulate in the bloodstream.
In some cases, related T-cell lymphoma diagnoses may also become relevant when we review a person’s pathology, symptoms, and treatment history. Some forms may remain limited to the skin for a period of time, while others may become more aggressive and require extensive medical treatment.
For patients and families, the emotional toll can be enormous. What first looked like a difficult skin condition may later become a cancer diagnosis involving biopsies, oncology consultations, long-term monitoring, and major uncertainty about the future.
What Are Symptoms of CTCL?
CTCL symptoms can vary depending on the subtype and stage, but some warning signs appear again and again. Common symptoms may include a persistent itchy rash, discolored patches of skin, thickened plaques, skin lesions, tumors, swollen lymph nodes, and skin that does not respond the way it should to standard eczema treatment. In some cases, the rash may worsen, spread, or change in appearance over time.
For many patients, the most unsettling part is that these symptoms can look very similar to severe eczema, dermatitis, or psoriasis. That can make diagnosis more difficult and delay the discovery of this serious underlying disease.
Is There a Connection Between Dupixent and CTCL?
The possible connection between Dupixent and CTCL is still being investigated. Published case reports, FDA safety-signal monitoring, and some observational studies have raised concern, while other researchers have argued that at least some reported cases may reflect misdiagnosed or previously undetected disease rather than a direct drug effect. Either way, the practical consequences for patients can be severe.
That concern has taken on added weight in light of regulatory action: in March 2025, the FDA placed Dupixent on its watch list of medications with potentially serious risks, citing reports of CTCL among users. Despite that development, the current prescribing information for Dupixent does not warn users about any potential cutaneous T-cell lymphoma risk.
Several lawsuits have been filed that alleged that Sanofi and Regeneron, the manufacturers of Dupixent, knew or should have known of a potential CTCL risk and failed to warn patients and prescribing physicians.
Lawsuits for CTCL After Dupixent Use?
Legal claims involving Dupixent and CTCL are actively developing. Attorneys handling dangerous drug and mass tort matters have been investigating these cases, and in early 2026, a motion was filed to transfer and consolidate related federal cases — a step that often signals the early formation of coordinated multidistrict litigation (MDL). That matters because early litigation often shapes the path of future claims, including the medical issues being examined, the diagnoses being screened, and the warning-related allegations being raised against the manufacturers.
This is also why timing matters. If you or your loved one developed cutaneous T-cell lymphoma, including diagnoses such as mycosis fungoides or Sézary syndrome, after using Dupixent, it is important to have your case reviewed sooner rather than later.
At Spotlight Justice, attorney Dena Young works directly with individuals and families facing high-stakes product liability and mass tort claims. If your lymphoma diagnosis came after Dupixent use, we can help you understand whether your experience may fit into emerging litigation and what steps can help protect your rights.
Can You File a Lawsuit After a Dupixent-Related CTCL Diagnosis?
Possibly. Whether you may have a viable claim will depend on your diagnosis, your medical history, your pathology and biopsy results, when you used Dupixent, and whether your case falls within the applicable filing deadlines. Families who lost a loved one after a Dupixent-related lymphoma diagnosis may also wish to seek legal guidance about their options.
In dangerous drug litigation, the legal questions often include whether the manufacturer knew or should have known of a serious risk, whether adequate warnings were given, whether doctors and patients were deprived of important safety information, and what harm followed as a result.
No two cases are exactly alike. That is why we look closely at your diagnosis, treatment history, available medical records, and timeline of events. At Spotlight Justice LLC, we focus on individualized representation for people dealing with serious, life-changing harm.
What Steps Should You Take Now?
If you or your loved one received a CTCL diagnosis after using Dupixent, it is important to take a few practical steps as soon as possible. What you do now may affect both your medical care and your ability to protect your legal rights.
- Continue following your doctors’ recommendations, and do not stop or change any prescribed medication without medical guidance.
- Preserve pathology reports, biopsy results, and other records that help establish when your symptoms changed and when your diagnosis was made.
- Save evidence related to Dupixent use, including prescription records, pharmacy information, packaging, insurance records, doctor visits, and treatment-related communications.
- Do not assume that waiting is harmless. Drug injury claims can involve filing deadlines, and delay can make it harder to preserve important evidence and reconstruct your timeline clearly.
Taking these steps early can make it easier to protect key records, understand what happened, and evaluate whether legal action may be appropriate. It can also make your next conversation with counsel far more productive.
Speak With Spotlight Justice LLC About Your Legal Options
A CTCL diagnosis can change everything. You may be trying to manage treatment, understand what your doctors are telling you, keep up with work or family responsibilities, and figure out whether the medication you trusted may be connected to what happened or may have affected how quickly the condition was recognized. You deserve answers, and you deserve to have your story taken seriously.
If you or your loved one used Dupixent and were later diagnosed with cutaneous T-cell lymphoma, including mycosis fungoides or Sézary syndrome, contact Spotlight Justice LLC today for a free, confidential consultation. We help individuals nationwide evaluate potential dangerous drug claims with the personal attention serious cases deserve. We can review your diagnosis, treatment history, and potential legal options, explain what emerging Dupixent-related litigation may mean for you, and help you decide what steps to take next.
To speak directly with attorney Dena Young, call 267-540-9604 or fill out our contact form today. At Spotlight Justice LLC, we give serious cases the personal attention they deserve and make sure your story is heard where it matters most.
Disclaimer: The articles on this blog are for informative purposes only and are no substitute for legal advice or an attorney-client relationship. If you are seeking legal advice, please contact our law firm directly.